Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$270.54 +3.40 (+1.27%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$270.75 +0.21 (+0.08%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
8
Buy
18

Based on 26 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 8 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for JNJ.

Consensus Price Target

$276.54
2.22% Upside
According to the 26 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $276.54. The highest price target for JNJ is $320.00, while the lowest price target for JNJ is $210.00. The average price target represents a forecasted upside of 2.22% from the current price of $270.54.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
11/22/25 to 11/22/26
1 Month Ago
10/23/25 to 10/23/26
3 Months Ago
8/24/25 to 8/24/26
1 Year Ago
11/22/24 to 11/22/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
3 Strong Buy rating(s)
Buy
17 Buy rating(s)
17 Buy rating(s)
18 Buy rating(s)
13 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$276.54$275.92$268.22$201.05
Forecasted Upside2.22% Upside4.46% Upside-1.79% Downside-1.39% Downside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonHealthcare CompaniesBroader Market
Consensus Rating Score
2.73
2.32
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside2.22% Upside121.33% Upside22.05% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Neutral News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/20/2026
Chris Schott
4 of 5 stars
Boost TargetNeutral$285.00 ➝ $300.00+10.94%
10/23/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 DowngradeBuy (B+) ➝ Buy (B-)
10/21/2026
Johnson Rice logo
Johnson Rice
2 of 5 stars
Ilya Zubkov
Not Rated
DowngradeBuy ➝ Hold
10/21/2026 DowngradeBuy ➝ Hold
10/20/2026 Set Target$300.00+15.64%
10/20/2026Reiterated RatingBuy
10/16/2026Boost TargetOverweight$275.00 ➝ $287.00+12.41%
10/15/2026Set Target$270.00+4.66%
10/15/2026Lower TargetOverweight$294.00 ➝ $292.00+14.11%
10/14/2026Lower TargetOutperform$276.00 ➝ $272.00+8.20%
10/14/2026Set Target$270.00+8.48%
10/14/2026Lower TargetOutperform$290.00 ➝ $280.00+12.03%
10/7/2026Reiterated RatingBuy$287.00+12.61%
10/5/2026Boost TargetBuy$298.00 ➝ $303.00+18.39%
9/29/2026Reiterated RatingNeutral$278.00+2.14%
9/10/2026Boost TargetBuy$290.00 ➝ $320.00+19.76%
8/3/2026Set Target$280.00+10.00%
7/29/2026Set Target$300.00+11.74%
7/16/2026 Reiterated RatingOutperform$305.00+22.51%
7/16/2026 Reiterated RatingBuy$282.00+13.92%
7/16/2026 UpgradeHold ➝ Strong-Buy
7/15/2026Set Target$260.00+5.03%
4/16/2026 Boost TargetOutperform$237.00 ➝ $246.00+3.65%
4/15/2026Boost TargetEqual Weight$234.00 ➝ $255.00+6.19%
2/19/2026 Boost TargetNeutral$180.00 ➝ $210.00-14.76%
1/27/2026Set Target$220.00-2.28%
1/5/2026 Boost TargetOutperform$225.00 ➝ $240.00+17.19%
12/11/2025 Reiterated RatingOutperform
7/17/2025 Reiterated RatingOverweight
4/24/2025UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:47 PM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, November 21, 2026. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson recently reported strong third-quarter results, beating analyst expectations with earnings per share of $2.59 against a consensus of $2.53, while revenue grew 5.9% year-over-year to $25.40 billion, demonstrating robust fundamental performance.
  • The stock is currently trading at $270.54, which is below the consensus price target of $276.54, suggesting potential upside as analysts maintain a "Moderate Buy" consensus rating for the company.
  • Recent clinical data for TREMFYA in axial psoriatic arthritis met key endpoints, showing significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation, which could strengthen the drug's commercial prospects.
  • Johnson & Johnson announced the first U.S. commercial installation of its OTTAVA surgical robot at a Houston hospital, marking an early step in bringing the platform to market and expanding its surgical-technology business.
  • The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies, which could broaden the drug’s growth potential if approved.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Several research analysts have recently downgraded the stock, including Johnson Rice and Weiss Ratings, while Morgan Stanley lowered its price target from $294.00 to $292.00, indicating some caution among Wall Street professionals.
  • Corporate insiders have been selling shares, with EVP Elizabeth Forminard selling 13,072 shares in November and EVP Timothy Schmid selling 33,597 shares in September, which may signal a lack of confidence from company leadership.
  • The stock recently crossed below its 50-day moving average, a technical indicator that often suggests a short-term downtrend or weakening momentum in the stock's price action.
  • Johnson & Johnson's dividend payout ratio is presently 81.21%, which is relatively high and may limit the company's ability to increase dividends or reinvest in growth without affecting its cash flow.
  • Erste Group Bank lowered its FY2027 earnings per share estimates for Johnson & Johnson, now expecting $11.31 per share down from a prior forecast of $11.46, reflecting a more conservative outlook on future earnings growth.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $276.54, with a high forecast of $320.00 and a low forecast of $210.00.

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 8 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 2.22% based on their 12-month stock forecasts.

Over the previous 90 days, Johnson & Johnson's stock had 3 downgrades and 1 upgrade by analysts.

Analysts like Johnson & Johnson more than other "healthcare" companies. The consensus rating for Johnson & Johnson is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how JNJ compares to other companies.


MarketBeat monitors more than a dozen sources for Johnson & Johnson analyst ratings, with the most recent rating issued on 11/20/2026.
From Our Partners